List view / Grid view

R&D

 

Celyad posts an update on its NKR-2 Trial

30 March 2016 | By Victoria White

Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...